Development of a Two-Component Vaccine for COVID-19
Author Information
Author(s): Sun Yi-Sheng, Xu Fang, Zhu Han-Ping, Xia Yong, Li Qiao-Min, Luo Yuan-Yuan, Lu Hang-Jing, Wu Bei-Bei, Wang Zhen, Yao Ping-Ping, Zhou Zhan
Primary Institution: Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China
Hypothesis
Can a two-component recombinant vaccine using RBD-Fc and NTD-Fc proteins enhance immune responses against COVID-19?
Conclusion
The two-component recombinant vaccine shows high immunogenicity and could serve as a potential booster strategy for COVID-19 vaccination.
Supporting Evidence
- The vaccine induced durable and potent IgG and neutralizing antibodies.
- Heterologous booster with the vaccine resulted in higher neutralizing antibody titers.
- The optimal RBD-Fc/NTD-Fc ratio was found to be 3:1.
- The vaccine elicited balanced Th1- and Th2-cell immune responses.
- Immunization with the vaccine showed no significant lung damage in mice.
Takeaway
Scientists created a new COVID-19 vaccine that combines two important parts to help our bodies fight the virus better.
Methodology
Female BALB/c mice were immunized with different ratios of RBD-Fc and NTD-Fc proteins, and their immune responses were measured through various assays.
Limitations
The study primarily involved animal models, and further research is needed to confirm efficacy in humans.
Participant Demographics
Female BALB/c mice, 8 weeks old.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website